Methane Breath Testing for Constipation Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for irritable bowel syndrome (IBS) and constipation-predominant IBS lack specificity and reliability, particularly in distinguishing between diarrhea and constipation subgroups, due to the absence of a definitive biomarker and the limitations of breath testing in diagnosing small intestinal bacterial overgrowth (SIBO).
Innovation Solution
Detection of abnormally elevated levels of methane and methanogenic organisms in breath, flatus, blood, or stool samples using techniques such as breath testing and gas chromatography, which indicate the presence of constipation or constipation-predominant IBS by identifying specific methanogenic organisms like Ruminococcus sp., Methanobrevibacter sp., Bacteroides sp., Clostridium sp., and Methanobacter sp.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If breath testing is used to diagnose SIBO, then diagnostic accessibility is improved, but reliability is worsened due to lack of specificity in distinguishing constipation subgroups
Solution Approach 1:
The patent changes the diagnostic parameter from traditional hydrogen breath testing to methane concentration measurement. By focusing on methane specifically rather than general gas production, the test achieves better specificity for constipation-predominant IBS while maintaining the accessibility of breath testing. The patent establishes that methane concentration >20 ppm in breath is highly predictive of constipation-predominant IBS.
2Adaptability or versatility
If complex diagnostic schema like Rome criteria are used, then diagnostic categorization is improved, but device complexity is worsened due to lack of objective biomarkers
Solution Approach 1:
The patent replaces the complex mechanical/clinical assessment system (Rome criteria requiring multiple symptom criteria evaluation) with a simpler biochemical measurement system. By using methane concentration measurement in breath, the patent provides an objective biomarker that directly indicates constipation-predominant IBS, eliminating the need for complex multi-parameter clinical assessment.
3Reliability
If direct culture is used to diagnose SIBO, then reliability is improved as gold standard, but ease of manufacture is worsened due to accessibility limitations
Solution Approach 1:
The patent uses breath methane concentration as an intermediary marker to indirectly diagnose SIBO and constipation-predominant IBS. Instead of requiring direct bacterial culture (which is invasive and limited to severe cases), the breath test provides a non-invasive, accessible proxy that correlates strongly with the presence of methanogenic bacteria and constipation symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a reliable method for diagnosing constipation and constipation-predominant IBS with high predictive value, as elevated methane levels are consistently associated with these conditions, offering improved diagnostic accuracy and treatment monitoring through antibiotic-induced normalization of breath tests.
Implementation Method 1
Excessive small intestinal gas can occur as a result of increased production of gas within the gut by bacterial fermentation. Hydrogen and methane are common gases excreted during breath testing.
Data Source
AI summary
Disclosed are methods of diagnosing constipation and constipation-predominant irritable bowel syndrome by screening for the presence of abnormally high levels of methane and/or methanogenic organisms in a subject.